retatrutide clinical trials sign up for weight loss: Study shows 30% body weight loss Retatrutide Helped Adults With Obesity

22, 2025, when the U.S Food and Drug Administration (FDA) approved oral Wegovy by Novo Nordisk as the first daily, oral GLP-1 pill for weight management

Were proud to be able to offer the most innovative treatments at launch, with the highest quality care, nationwide. Despite GLP-1s being available for years, there are still so many people holding back from treatment due to stigma, lack of access, or concern over how the medication will fit into their lifestyle, said Laura Steele, Group Vice President of U.S

Side effects may be more prominent during treatment initiation or dose escalation

Building a sustainable daily routine around GLP-1 drops Long-term success with sublingual GLP-1 therapy depends on making the administration routine feel effortless rather than burdensome